Drug intelligence / Profile preview

schisandrin b

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral (dietary Supplement), Topical (potential Preclinical Studies)
01

Overview

Schisandrin b is a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra chinensis. It is widely studied for its **antioxidant**, **anti-inflammatory**, **hepatoprotective**, **cardioprotective**, **neuroprotective**, and **antitumor** properties. Its mechanism of action involves upregulating the cellular antioxidant response, increasing the activity of superoxide dismutase (SOD), glutathione-related enzymes, and directly scavenging reactive oxygen species. It inhibits key inflammatory pathways, including TNF-α and IL-1β, and modulates neuroinflammation via toll-like receptor–mediated pathways (suppressing NF-κB signaling). In cancer models, schisandrin b induces apoptosis, cell cycle arrest, and inhibits cell proliferation, invasion, and migration by acting on pathways such as PI3K/Akt/mTOR, and matrix metalloproteinases. Schisandrin b exhibits low toxicity in animal studies and is under active preclinical research as a potential therapeutic for tumors, liver disorders, cardiovascular conditions, and neurodegenerative diseases[1][3][6].

Other names
schizandrin bγ-schisandrin(+)-gamma-schizandrinGOMISIN Nwuweizisu Bchisandrin BS(-)-SCHISANDRINwiweizisu
02

Targets

AKT (RAC-alpha serine/threonine-protein kinase)G6PD (Glucose-6-phosphate dehydrogenase)GST (Glutathione S-transferase alpha 3)GSR (Glutathione reductase)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)mTOR (Mammalian target of rapamycin kinase)NF-κBMisfolded SOD1TLR (Toll-like receptors)TNFA (Tumor necrosis factor alpha (soluble))MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)

Beyond the preview

Go deeper on schisandrin b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on schisandrin b.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call